AbbVie Inc (ABBV)vsMednax Inc (MD)
ABBV
AbbVie Inc
$246.04
+0.89%
HEALTHCARE · Cap: $430.82B
MD
Mednax Inc
$27.08
+2.15%
HEALTHCARE · Cap: $2.11B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 3233% more annual revenue ($64.39B vs $1.93B). ABBV leads profitability with a 9.8% profit margin vs 9.0%. MD appears more attractively valued with a PEG of 0.24. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
MD
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-63.1%
Fair Value
$150.90
Current Price
$246.04
$95.14 premium
Margin of Safety
+64.6%
Fair Value
$60.68
Current Price
$27.08
$33.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 39.6%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 50.0% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
3.9% revenue growth
Distress zone — elevated risk
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : MD
The strongest argument for MD centers on PEG Ratio, EPS Growth, P/E Ratio. PEG of 0.24 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 68.9x leaves little room for execution misses.
Bear Case : MD
The primary concerns for MD are Revenue Growth, Altman Z-Score, Free Cash Flow.
Key Dynamics to Monitor
MD carries more volatility with a beta of 0.66 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 67/100) and 10.2% revenue growth. MD offers better value entry with a 64.6% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Mednax Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
MEDNAX, Inc., provides neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialties in the United States and Puerto Rico. The company is headquartered in Sunrise, Florida.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?